Insider Equity Grants Show Terns Pharma’s Bold Move Ahead of Liver‑Cancer Trial Success
Insider equity deals show Terns Pharmaceuticals’ leadership betting on its liver‑cancer pipeline and FDA milestones—potential upside but watch for 2030 dilution risks.
4 minutes to read